title: Current status of therapy for breast cancer worldwide and in Japan.
abstract: The results of clinical trials conducted in Europe and North America have been incorporated into treatment strategies for breast cancer in Japan. Despite the use of similar treatment regimens, why has mortality from breast cancer been increasing in Japan? Procedures for surgical treatment and sentinel lymph node biopsy in breast cancer do not differ between Japan and Western countries, but the strategies for radiotherapy differ slightly. Hormonal therapy is now selected on the basis of scientific evidence, and similar regimens are used in Japan and Western countries. As for postoperative adjuvant chemotherapy, an anthracycline plus cyclophosphamide and taxane-based regimens are standard treatments in Japan and Western countries. In 2009, however, the results of two large clinical studies designed to determine whether intravenous or oral treatment was superior for postoperative adjuvant chemotherapy were reported in Japan. Both studies showed that relapse-free survival and overall survival (OS) at 5 years after surgery were similar for a combination of cyclophosphamide, methotrexate, and 5-fluorouracil and for tegafur/uracil. Many chemotherapeutic agents that are used to treat recurrent or metastatic breast cancer have not yet been approved in Japan. As for molecular targeted therapy, some agents that target the human epidermal growth factor receptor family have been approved in Japan, whereas angiogenesis inhibitors have not. The results of many clinical trials have been incorporated into clinical practice in Japan, therefore, the outcomes of breast cancer therapy have surpassed those in other countries. Many pivotal clinical trials have been conducted outside Japan. Treatment regimens that have been developed on the basis of these studies might be suitable for the management of breast cancer in Western women, but not for Japanese women because of differences in genetic factors, physique, body mass index, pharmacokinetics, and drug metabolism. Such regimens should be modified on the basis of the characteristics of breast cancer in Japan to develop treatment that is optimally suited for Japanese women. In particular, local studies of pharmacokinetics, pharmacodynamics, and optimal dose levels and treatment intervals should be carefully performed. The establishment of treatment regimens optimally suited for Japanese patients with breast cancer could put the brakes on the trend towards increasing mortality from breast cancer in Japan.
authors: Youngjin Park, Tomoaki Kitahara, Ryuichi Takagi, Ryoji Kato, Department of Surgery, Sakura Medical Center, School of Medicine, Faculty of Medicine, Toho University, Sakura, Chiba Prefecture 285-8741, Japan.
authors: Youngjin
authors: Y
authors: Park
authors: Tomoaki
authors: T
authors: Kitahara
authors: Ryuichi
authors: R
authors: Takagi
authors: Ryoji
authors: R
authors: Kato
references: Clin Cancer Res. 2009 Apr 1;15(7):2552-8
references: 19318484
references: Breast Cancer. 2008;15(1):3-4
references: 18224385
references: J Clin Oncol. 2008 Apr 10;26(11):1810-6
references: 18347007
references: J Clin Oncol. 2005 Nov 1;23(31):7794-803
references: 16172456
references: N Engl J Med. 2007 Dec 27;357(26):2666-76
references: 18160686
references: Lancet Oncol. 2008 Jan;9(1):45-53
references: 18083636
references: N Engl J Med. 1985 Mar 14;312(11):674-81
references: 3883168
references: N Engl J Med. 2003 Aug 7;349(6):546-53
references: 12904519
references: N Engl J Med. 2006 Dec 28;355(26):2733-43
references: 17192538
references: Ann Oncol. 2004 Mar;15(3):440-9
references: 14998846
references: N Engl J Med. 2005 Oct 20;353(16):1659-72
references: 16236737
references: Breast Cancer Res Treat. 2010 Feb;119(3):633-41
references: 19936917
references: Br J Cancer. 2009 Aug 18;101(4):598-604
references: 19638976
references: J Clin Oncol. 2009 Mar 20;27(9):1368-74
references: 19204202
references: J Natl Cancer Inst. 2002 Aug 7;94(15):1143-50
references: 12165639
references: J Clin Oncol. 2011 Jun 20;29(18):2459-65
references: 21555686
references: N Engl J Med. 2005 Oct 20;353(16):1673-84
references: 16236738
references: J Clin Oncol. 2008 Apr 20;26(12):1993-9
references: 18421051
references: J Clin Oncol. 2002 Dec 15;20(24):4621-7
references: 12488405